| Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Massive hemolysis in paroxysmal nocturnal hemoglobinuria after switching from proximal complement inhibitor to anti-C5 therapy: A lesson not to be forgotten |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Clinical decision-making and treatment of myelodysplastic syndromes |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| The Importance of Controlling Terminal Complement Activity and Intravascular Hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Haploidentical stem cell transplantation (haplo-SCT) represents the main alternative for children with inherited bone marrow failure syndrome (I-BMF) lacking a matched donor. This retrospective study, conducted on behalf of the EBMT SAAWP and PDWP, aims t |
|
American Society of Clinical Oncology Educational Book |
Myelodysplastic Syndromes (MDS) |
| New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes |
|
American Society of Clinical Oncology Educational Book |
Myelodysplastic Syndromes (MDS) |
